Qtern is owned by Astrazeneca Ab.
Qtern contains Dapagliflozin; Saxagliptin Hydrochloride.
Qtern has a total of 8 drug patents out of which 0 drug patents have expired.
Qtern was authorised for market use on 27 February, 2017.
Qtern is available in tablet;oral dosage forms.
Qtern can be used as treatment of type 2 diabetes mellitus; method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin; method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin, treatment of type 2 diabetes mellitus, treatment of type 2 diabetes mellitus; method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin.
The generics of Qtern are possible to be released after 16 December, 2029.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(4 months from now) | |
US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(2 years from now) | |
US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(2 years from now) | |
US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | May 2, 2022 |
New Indication (I) | May 2, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 February, 2017
Treatment: Treatment of type 2 diabetes mellitus; Method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; Method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin
Dosage: TABLET;ORAL
25
United States
14
Japan
13
China
11
Brazil
11
European Union
10
Korea, Republic of
9
Spain
9
Mexico
9
Taiwan, Province of China
8
Norway
8
Canada
7
Russia
7
New Zealand
7
Hong Kong
7
EA
7
Israel
6
Portugal
6
Argentina
6
Peru
6
Hungary
6
Slovenia
6
Poland
6
Denmark
5
Croatia
5
Australia
4
Malaysia
4
South Africa
4
Lithuania
4
ME
4
RS
3
Cyprus
3
Ukraine
2
Germany
2
Singapore
2
Colombia
2
Philippines
2
Austria
2
Belgium
2
India
2
Luxembourg
2
Georgia
2
Chile
1
Turkey
1
Uruguay
1
Egypt
1
Iceland
1
Yugoslavia
1
Czech Republic
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic